(-0.13%) 5 462.00 points
(-0.11%) 39 071 points
(0.13%) 17 742 points
(-0.04%) $80.80
(-3.45%) $2.66
(-0.77%) $2 312.90
(0.20%) $28.93
(1.91%) $1 005.20
(0.32%) $0.936
(0.75%) $10.68
(0.50%) $0.792
(0.01%) $87.50
Live Chart Being Loaded With Signals
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases...
Stats | |
---|---|
आज की मात्रा | 192 029 |
औसत मात्रा | 193 348 |
बाजार मूल्य | 53.57M |
EPS | $-0.460 ( Q1 | 2024-05-09 ) |
अगली कमाई की तारीख | ( $-0.360 ) 2024-08-08 |
Last Dividend | $0.361 ( 2023-03-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.150 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-17 | Morris Richard Steven | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Klichinsky Michael | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Kelly Steven | Buy | 125 000 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 38 700 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 0 |
INSIDER POWER |
---|
100.00 |
Last 7 transactions |
Buy: 1 112 700 | Sell: 0 |
मात्रा सहसंबंध
Carisma Therapeutics, सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
OZEM | 1 |
BNZI | 0.962 |
LUXH | 0.96 |
AAME | 0.942 |
CHUY | 0.936 |
FRGT | 0.934 |
AMPL | 0.933 |
HPKEW | 0.933 |
DYFI | 0.932 |
AEON | 0.931 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
JAJWX | -0.955 |
DTI | -0.944 |
ATMV | -0.94 |
CNRLX | -0.94 |
NEOV | -0.928 |
OCMAX | -0.928 |
IROH | -0.925 |
FORL | -0.922 |
QTTB | -0.92 |
ISRL | -0.919 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Carisma Therapeutics, सहसंबंध - मुद्रा/वस्त्र
Carisma Therapeutics, वित्तीय
Annual | 2023 |
राजस्व: | $14.92M |
सकल लाभ: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2023 |
राजस्व: | $14.92M |
सकल लाभ: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2022 |
राजस्व: | $9.83M |
सकल लाभ: | $3.74M (38.07 %) |
EPS: | $-575.42 |
Financial Reports:
No articles found.
Carisma Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.361 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.361 | 2023-03-08 |
Last Dividend | $0.361 | 2023-03-08 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-08 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.361 | -- |
Avg. Dividend % Per Year | 0.94% | -- |
Score | 0.39 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.361 | 2.82% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Mar 2023 | $0.361 | 03 Feb 2023 | 07 Mar 2023 | 08 Mar 2023 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -5.39 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.101 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.16 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.30 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.102 | -1.500 | 8.31 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -103.61 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.968 | -1.935 | [0 - 20] |
debtEquityRatioTTM | 0.688 | -1.500 | 7.25 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.656 | 1.000 | 2.40 | 2.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | -5.66 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.204 | 0.800 | -1.972 | -1.577 | [0.5 - 2] |
Total Score | -1.801 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.580 | 1.000 | -0.160 | 0 | [1 - 100] |
returnOnEquityTTM | -2.16 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.645 | -1.935 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0261 | 1.500 | -3.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Carisma Therapeutics,
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं